ana
عضو نشط
- التسجيل
- 24 فبراير 2006
- المشاركات
- 169
eFoodSafety.com, Inc. Completes Bird Flu Formulation; EFSF Believes It Has Formulated the 'Total Solution' to the Potential Bird Flu Pandemic
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--March 27, 2006--Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF), announced today that eFoodSafety.com, Inc. has completed its product formulations on what it calls the "Total Solution" to the potential Bird Flu pandemic. eFoodSafety's Citroxin formulation has definitively proven in independent laboratory testing to eliminate the H9N2 virus, which is the surrogate organism used in all laboratory testing for the Bird Flu, on both hard and porous surfaces.
eFoodSafety's Citroxin formulation can be sprayed on bird cages and hen houses without it being harmful to animals or humans in surrounding areas if ingested.
Humans who have contracted the H5N1 virus, commonly known as Bird Flu, can rely on eFoodSafety's Citroxin O2 formulation, an ingestible product that the company believes will prove to have dramatic effects on the Bird Flu virus. The Citroxin O2 formulation is currently undergoing human clinical trials on the Influenza Viruses A and B, however testimonials from humans who have taken the product with influenza-like symptoms indicate very promising results.
The company further reports that interest in the Citroxin formulations from large multi-billion dollar pharmaceutical corporations has been very encouraging and anticipates pursuing all opportunities presented.
"It is eFoodSafety's contention that these two products can prevent the spread and effectively treat the potential pandemic Bird Flu virus. We anticipate the product will soon be ready for mass production and distribution," stated Mrs. Gruden.
About eFoodSafety.com, Inc.
eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight-loss formula focusing on the body's 24-hour metabolic processes.
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--March 27, 2006--Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF), announced today that eFoodSafety.com, Inc. has completed its product formulations on what it calls the "Total Solution" to the potential Bird Flu pandemic. eFoodSafety's Citroxin formulation has definitively proven in independent laboratory testing to eliminate the H9N2 virus, which is the surrogate organism used in all laboratory testing for the Bird Flu, on both hard and porous surfaces.
eFoodSafety's Citroxin formulation can be sprayed on bird cages and hen houses without it being harmful to animals or humans in surrounding areas if ingested.
Humans who have contracted the H5N1 virus, commonly known as Bird Flu, can rely on eFoodSafety's Citroxin O2 formulation, an ingestible product that the company believes will prove to have dramatic effects on the Bird Flu virus. The Citroxin O2 formulation is currently undergoing human clinical trials on the Influenza Viruses A and B, however testimonials from humans who have taken the product with influenza-like symptoms indicate very promising results.
The company further reports that interest in the Citroxin formulations from large multi-billion dollar pharmaceutical corporations has been very encouraging and anticipates pursuing all opportunities presented.
"It is eFoodSafety's contention that these two products can prevent the spread and effectively treat the potential pandemic Bird Flu virus. We anticipate the product will soon be ready for mass production and distribution," stated Mrs. Gruden.
About eFoodSafety.com, Inc.
eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight-loss formula focusing on the body's 24-hour metabolic processes.
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission
